1
|
Tom KR, Knorr KB, Davis CE. Next Generation Identification system: Latent print matching algorithm and casework practices. Forensic Sci Int 2022; 332:111180. [PMID: 35063814 DOI: 10.1016/j.forsciint.2022.111180] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 09/29/2021] [Accepted: 01/05/2022] [Indexed: 11/04/2022]
Abstract
The development of automated fingerprint identification systems (AFIS) revolutionized casework in the friction ridge community. Through the evolution of AFIS development, algorithms have become increasingly sensitive and specific. Internal validation studies conducted by the Federal Bureau of Investigation Laboratory Division's Latent Print Units (LPU) assessed the performance of the Next Generation Identification (NGI) system's latent print matching algorithm under the various encoding methods of the Multi-Biometric Identification System (MBIS) platform for the purpose of casework implementation. Based on the results of these studies, casework practices in the LPU have become more streamlined and efficient. The increase in accuracy of the latent print matching algorithm has reduced the number of candidates compared per search. For fingerprints, the results showed the best indicator for the correct mate being the number one candidate was the difference in score between the first and second candidate. When the score difference was 1200 or higher, the first candidate was mated in 99.3% of the trials. This understanding may allow for additional quality assurance measures to be implemented in casework.
Collapse
Affiliation(s)
- Kyle R Tom
- Latent Print Support Unit, Federal Bureau of Investigation Laboratory Division, 2501 Investigation Parkway, Quantico, VA 22135, USA.
| | - Kathryn B Knorr
- Latent Print Support Unit, Federal Bureau of Investigation Laboratory Division, 2501 Investigation Parkway, Quantico, VA 22135, USA.
| | - Christine E Davis
- Latent Print Support Unit, Federal Bureau of Investigation Laboratory Division, 2501 Investigation Parkway, Quantico, VA 22135, USA.
| |
Collapse
|
2
|
Casula L, Lai F, Pini E, Valenti D, Sinico C, Cardia MC, Marceddu S, Ailuno G, Fadda AM. Pulmonary Delivery of Curcumin and Beclomethasone Dipropionate in a Multicomponent Nanosuspension for the Treatment of Bronchial Asthma. Pharmaceutics 2021; 13:pharmaceutics13081300. [PMID: 34452261 PMCID: PMC8401312 DOI: 10.3390/pharmaceutics13081300] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 08/16/2021] [Accepted: 08/18/2021] [Indexed: 11/16/2022] Open
Abstract
Curcumin has shown a potential extraordinary activity as an add-on ingredient in asthma treatment, due to its immunomodulatory and anti-inflammatory mechanism of action. However, its low water solubility and bioavailability lead to a poor therapeutic effect, which can be overcome by its formulation as nanocrystals. The aim of this study was to prepare a multicomponent formulation for the delivery of curcumin (CUR) and beclomethasone dipropionate (BDP) into the lungs as water-based nanosuspensions (NS). Single component formulations (CUR-NS, BDP-NS) and a multicomponent formulation (CUR+BDP-NS) were prepared through a wet ball media milling technique, using P188 as a non-toxic stabilizer. Characterization was carried out in terms of size, size distribution, zeta potential, nanocrystals morphology, and solid-state properties. Moreover, the inhalation delivery efficiency was studied with Next Generation Impactor (NGI, Apparatus E Ph. Eu). CUR-NS was optimized and showed a long-term stability and improved nanocrystals apparent solubility. The three formulations exhibited a nanocrystal mean diameter in the range of 200-240 nm and a homogenous particle size distribution. Aggregation or sedimentation phenomena were not observed in the multicomponent formulation on 90 days storage at room temperature. Finally, the nebulization tests of the three samples showed optimal aerodynamic parameters and MMAD < 5 µm.
Collapse
Affiliation(s)
- Luca Casula
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Francesco Lai
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Elena Pini
- DISFARM, Sezione di Chimica Generale e Organica “A. Marchesini”, Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy;
| | - Donatella Valenti
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Chiara Sinico
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Maria Cristina Cardia
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Salvatore Marceddu
- Istituto di Scienze delle Produzioni Alimentari (ISPA)-CNR, Sez. di Sassari, 07040 Baldinca, Italy;
| | - Giorgia Ailuno
- Department of Pharmacy, University of Genova, 16147 Genova, Italy;
| | - Anna Maria Fadda
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
- Correspondence: ; Tel.: +39-070-675-8565
| |
Collapse
|
3
|
Abstract
The induction port (IP) for aerosol analysis with the Next Generation Pharmaceutical Impactor as monographed in the United States and European pharmacopoeia (USPIP) lacks physiological relevance, which, amongst other reasons, has been identified as critical for the predictability of in vitro aerosol data to lung deposition observed in vivo. In this publication, we report the impact of replacing the USPIP with two modified induction ports, which were designed based around geometries derived from a computer tomographic scan of a human trachea and the distal section of the USPIP. Test formulations were selected on the basis of availability of in vivo lung deposition data so that results obtained in vitro could be evaluated for their predictability. All formulations assessed showed increased deposition in the modified induction ports, and different mechanisms of particle deposition have been identified. In vitro predictions of the lung deposition were found to correlate well with the in vivo observations reported using the modified induction ports. Furthermore, the quality of the correlation was found superior to the one achieved with the USPIP with an average deviation of the predicted from observed values (n = 10) of 6 ± 4, 12 ± 6, and 16 ± 6% for the modified induction ports (mIP and mIPext) and the USPIP, respectively, when using a fine particle fraction (FPF) cutoff value of 5 μm. Using a FPF cutoff value of 3 μm yielded a more accurate in vitro-in vivo correlation with an average deviation of the predicted from observed values of 5 ± 4, 7 ± 5, and 8 ± 4% for the mIP, mIPext, and USPIP, respectively. For both FPF size cutoff values, the mIP yielded the most accurate in vitro-in vivo correlation.
Collapse
Affiliation(s)
- Kai Berkenfeld
- Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn 53121, Germany
| | - Kathryn Hauschild
- Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn 53121, Germany
| | - Jason T McConville
- Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn 53121, Germany.,College of Pharmacy, University of New Mexico, Albuquerque, New Mexico 87131, United States
| | - Alf Lamprecht
- Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn 53121, Germany.,College of Pharmacy, University of New Mexico, Albuquerque, New Mexico 87131, United States
| |
Collapse
|
4
|
Berkenfeld K, McConville JT, Lamprecht A. Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy. Expert Opin Drug Deliv 2020; 17:305-322. [PMID: 32017637 DOI: 10.1080/17425247.2020.1720644] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Introduction: Recently, tuberculosis was reported as the leading cause of death from a single infectious agent. Standard therapy includes administration of four first-line antibiotics, i.e. rifampicin, isoniazid, ethambutol, and pyrazinamide over a period of at least 26 weeks, which in case of rifampicin oftentimes is accompanied by unwanted side effects and variable bioavailability that compromise a positive therapeutic outcome. As the main site of infection is the lungs, it is desirable to develop a therapeutic formulation to be administered via the pulmonary route.Areas covered: This work presents a literature review on studies investigating inhalable dry powder formulations including rifampicin in the context of an experimental tuberculosis therapy, with a special focus on aerosol performance.Expert opinion: It was found that formulation approaches involving different strategies and functional excipients are under investigation but as of now, no formulation has managed to leap into commercial clinical testing. Reasons for this might not primarily be associated with a lack of suitable candidates, but amongst others a lack of suitable in vitro models to assess the efficacy, therapeutic benefit, and cost-effectiveness of the candidate formulations.
Collapse
Affiliation(s)
- Kai Berkenfeld
- Department of Pharmaceutics, Institute of Pharmacy, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany
| | - Jason T McConville
- Department of Pharmaceutics, Institute of Pharmacy, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.,Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, USA
| | - Alf Lamprecht
- Department of Pharmaceutics, Institute of Pharmacy, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.,Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, USA
| |
Collapse
|
5
|
Stokes J. Technical note: Next generation identification - A powerful tool in cold case investigations. Forensic Sci Int 2019; 299:74-79. [PMID: 30959402 DOI: 10.1016/j.forsciint.2019.03.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 03/11/2019] [Accepted: 03/19/2019] [Indexed: 11/24/2022]
Abstract
Ever changing technology is allowing law enforcement/crime laboratories the ability to use new advances to solve old cases. Exonerations through advances in DNA testing have become increasingly common. However, other forensic disciplines are also utilizing new technologies, which are providing investigative leads and case closures. One advancement is the Federal Bureau of Investigation's Next Generation Identification (NGI) biometric system, which has enhanced the field of print identification. The Oklahoma State Bureau of Investigation (OSBI) Latent Evidence Unit is utilizing NGI to assist in solving "Cold Cases." While the OSBI cold case project has been successful, reviewing old evidence and case files, while keeping up with current casework, can be challenging. However, the recognition and application of such powerful technology is warranted, as demonstrated by the success that has been achieved.
Collapse
Affiliation(s)
- Jim Stokes
- Oklahoma State Bureau of Investigation, 800 E. 2nd Street, Edmond, OK, 73034, United States.
| |
Collapse
|
6
|
Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat ® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis 2017; 12:1565-1577. [PMID: 28603412 PMCID: PMC5457178 DOI: 10.2147/copd.s115886] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Combining in vitro mouth-throat deposition measurements, cascade impactor data and computational fluid dynamics (CFD) simulations, four different inhalers were compared which are indicated for chronic obstructive pulmonary disease (COPD) treatment. METHODS The Respimat inhaler, the Breezhaler, the Genuair, and the Ellipta were coupled to the idealized Alberta throat model. The modeled dose to the lung (mDTL) was collected downstream of the Alberta throat model using either a filter or a next generation impactor (NGI). Idealized breathing patterns from COPD patient groups - moderate and very severe COPD - were applied. Theoretical lung deposition patterns were assessed by an individual path model. RESULTS AND CONCLUSION For the Respimat the mDTL was found to be 59% (SD 5%) for the moderate COPD breathing pattern and 67% (SD 5%) for very severe COPD breathing pattern. The percentages refer to nominal dose (ND) in vitro. This is in the range of 44%-63% in vivo in COPD patients who display large individual variability. Breezhaler showed a mDTL of 43% (SD 2%) for moderate disease simulation and 51% (SD 2%) for very severe simulation. The corresponding results for Genuair are mDTL of 32% (SD 2%) for moderate and 42% (SD 1%) for very severe disease. Ellipta vilanterol particles showed a mDTL of 49% (SD 3%) for moderate and 55% (SD 2%) for very severe disease simulation, and Ellipta fluticasone particles showed a mDTL of 33% (SD 3%) and 41% (SD 2%), respectively for the two breathing patterns. Based on the throat output and average flows of the different inhalers, CFD simulations were performed. Laminar and turbulent steady flow calculations indicated that deposition occurs mainly in the small airways. In summary, Respimat showed the lowest amount of particles depositing in the mouth-throat model and the highest amount reaching all regions of the simulation lung model.
Collapse
Affiliation(s)
- Anna-Maria Ciciliani
- Institute of Pharmacy and Biochemistry, Faculty 09 (Chemistry, Pharmaceutics and Geosciences), Johannes Gutenberg University, Mainz.,Analytical Development Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
| | - Peter Langguth
- Institute of Pharmacy and Biochemistry, Faculty 09 (Chemistry, Pharmaceutics and Geosciences), Johannes Gutenberg University, Mainz
| | - Herbert Wachtel
- Analytical Development Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
| |
Collapse
|
7
|
Zhang X, Liu Q, Hu J, Xu L, Tan W. An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation. Acta Pharm Sin B 2014; 4:79-85. [PMID: 26579368 PMCID: PMC4590724 DOI: 10.1016/j.apsb.2013.12.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Revised: 12/24/2013] [Accepted: 12/26/2013] [Indexed: 12/14/2022] Open
Abstract
An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.
Collapse
Affiliation(s)
- Xuemei Zhang
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
| | - Qing Liu
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
| | - Junhua Hu
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
| | - Ling Xu
- Key-Pharma Biomedical Inc., Dongguan 523000, China
| | - Wen Tan
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
| |
Collapse
|
8
|
Tewes F, Ehrhardt C, Healy AM. Superparamagnetic iron oxide nanoparticles (SPIONs)-loaded Trojan microparticles for targeted aerosol delivery to the lung. Eur J Pharm Biopharm 2013; 86:98-104. [PMID: 24055690 DOI: 10.1016/j.ejpb.2013.09.004] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Revised: 08/19/2013] [Accepted: 09/07/2013] [Indexed: 12/29/2022]
Abstract
Targeted aerosol delivery to specific regions of the lung may improve therapeutic efficiency and minimise unwanted side effects. Targeted delivery could potentially be achieved with porous microparticles loaded with superparamagnetic iron oxide nanoparticles (SPIONs)-in combination with a target-directed magnetic gradient field. The aim of this study was to formulate and evaluate the aerodynamic properties of SPIONs-loaded Trojan microparticles after delivery from a dry powder inhaler. Microparticles made of SPIONs, PEG and hydroxypropyl-β-cyclodextrin (HPβCD) were formulated by spray drying and characterised by various physicochemical methods. Aerodynamic properties were evaluated using a next generation cascade impactor (NGI), with or without a magnet positioned at stage 2. Mixing appropriate proportions of SPIONs, PEG and HPβCD allowed Trojan microparticle to be formulated. These particles had a median geometric diameter of 2.8±0.3μm and were shown to be sensitive to the magnetic field induced by a magnet having a maximum energy product of 413.8kJ/m(3). However, these particles, characterised by a mass median aerodynamic diameter (MMAD) of 10.2±2.0μm, were considered to be not inhalable. The poor aerodynamic properties resulted from aggregation of the particles. The addition of (NH4)2CO3 and magnesium stearate (MgST) to the formulation improved the aerodynamic properties of the Trojan particles and resulted in a MMAD of 2.2±0.8μm. In the presence of a magnetic field on stage 2 of the NGI, the amount of particles deposited at this stage increased 4-fold from 4.8±0.7% to 19.5±3.3%. These Trojan particles appeared highly sensitive to the magnetic field and their deposition on most of the stages of the NGI was changed in the presence compared to the absence of the magnet. If loaded with a pharmaceutical active ingredient, these particles may be useful for treating localised lung disease such as cancer nodules or bacterial infectious foci.
Collapse
Affiliation(s)
- Frederic Tewes
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin, Ireland; INSERM U-1070, Pôle Biologie-Santé, Faculté de Médecine & Pharmacie, Université de Poitiers, Poitiers Cedex, France
| | - Carsten Ehrhardt
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin, Ireland
| | - Anne Marie Healy
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin, Ireland.
| |
Collapse
|